Dr. Asiya Khan, GIMS Greater Noida, India.
Dr. Asiya Khan is a highly accomplished scientist at the Multi-Disciplinary Research Unit (MRU), Government Institute of Medical Sciences (GIMS), Greater Noida. Born on December 15th, 1983, she has built a robust career in the fields of cervical cancer research and molecular diagnostics 🧬. With a remarkable trajectory from her tenure at AIIMS-New Delhi to her current position, Dr. Khan has been instrumental in developing cancer-specific panels and executing high-impact translational research. She has authored over 20 peer-reviewed publications and book chapters, reflecting her dedication to scientific advancement. Her current focus includes the Next Generation Sequencing (NGS) platform and innovation in cancer therapeutics and diagnostics. Dr. Khan’s multidisciplinary background and deep insight into immune markers and oncogenic pathways have made significant contributions to cancer biology research in India and beyond 🌍.
👩🔬 Profile
Googlescholar
🎓 Education
Dr. Asiya Khan pursued her Ph.D. in Molecular Biology at the All India Institute of Medical Sciences (AIIMS), New Delhi, where she focused on the immunopathogenesis of women-specific cancers 🎓. Her doctoral work addressed the complex role of complement regulatory proteins like CD55, CD59, and CD46 in HPV-related cervical cancer progression. Through extensive clinical and laboratory research, she became proficient in various advanced molecular biology techniques such as siRNA transfection, PCR-based diagnostics, ELISA, and protein interaction studies. Her education laid a strong foundation for her future in translational research, equipping her with a versatile toolkit to tackle major public health challenges related to women’s cancers. Additionally, her Ph.D. research gained widespread academic recognition, leading to multiple high-impact publications 📚. She has also undergone continuous professional development, staying current with the latest advancements in molecular diagnostics and cancer genomics.
🧪 Experience
With over a decade of progressive experience, Dr. Asiya Khan has held pivotal research roles at premier medical institutions 🏥. Her early career began at AIIMS-New Delhi, where she engaged in groundbreaking research on immune markers in cervical and breast cancer. At AIIMS, she was deeply involved in both national and international projects related to women’s health, infectious diseases, and cancer diagnostics. Currently serving as a Scientist at GIMS, Greater Noida, she leads research on the NGS platform, focusing on oral and breast cancer panel designs. Dr. Khan is also responsible for department-wide research management, project writing, and manuscript development. Her leadership in translational innovation, drug resistance studies, and diagnostics has yielded tangible impacts. Notably, her systematic review on endocrine resistance in breast cancer was recently accepted in Cancers, a journal with an IF of 5.2. Her career reflects a deep commitment to improving clinical outcomes through evidence-based research and innovation 💡.
🔬 Research Interests
Dr. Khan’s core research interests lie in cervical cancer, breast cancer, and molecular diagnostics 🧬. She has extensively explored the role of immune-regulatory proteins in HPV-mediated cervical cancer, contributing to the understanding of carcinogenesis at the molecular level. Her work delves into drug resistance, the development of cancer biomarkers, and the discovery of novel therapeutic targets. Using cutting-edge tools like NGS, CRISPR-based diagnostics, and protein-ligand interaction models, Dr. Khan continues to explore ways to personalize treatment strategies. Her translational approach is evident in projects investigating Nimbin analogs for NF-κB inhibition and siRNA therapies targeting ETS-1. In infectious disease research, she has highlighted the emergence of NDM-1 resistance and led population-based studies on hydatidosis and Rickettsial diseases. Her work bridges the gap between lab and clinic, with a vision to revolutionize early cancer detection and intervention 💊.
🏆 Awards & Achievements
Dr. Asiya Khan’s scientific journey is marked by numerous achievements 🌟. She has published more than 20 high-quality research papers and book chapters in journals such as Seminars in Cancer Biology (IF 14.5), Frontiers in Oncology (IF 5.7), and Gene (IF 3.9). Her groundbreaking research on CRPs in cervical cancer cells and ETS-1 in breast cancer has garnered attention for its diagnostic and therapeutic relevance. Her systematic review on endocrine resistance was recently accepted by Cancers (IF 5.2), solidifying her reputation in oncology research. Notably, she was the first to isolate NDM-1 clinical strains from Kashmir and has led state-wide epidemiological investigations in India. She has also developed rapid diagnostic assays, including a Modified MODS assay for tuberculosis detection, suitable for resource-limited settings. Her work reflects both innovation and public health relevance, making her a strong candidate for national and international research awards 🏅.
📚 Publication Top Notes
Cancer drug resistance: A fleet to conquer
Mannitol production from glycerol by resting cells of Candida magnoliae
NDM-1 (New Delhi metallo beta lactamase-1) producing Gram-negative bacilli: Emergence & clinical implications
Genetic landscape of gallbladder cancer: global overview
Breast cancer invasion and progression by MMP-9 through Ets-1 transcription factor
Sero-epidemiological survey of human cystic echinococcosis in Kashmir, North India
Nasal carriage of methicillin-resistant Staphylococcus aureus among healthy population of Kashmir, India
Cancer immunotherapy: A promising dawn in cancer research
Efficacy of complementary therapies in the quality of life of breast cancer survivors
Detection of hydatid-specific antibodies in the serum and urine for the diagnosis of cystic echinococcosis in patients from the Kashmir Valley, India